A larger number of the residues in the GLP-2 and glicentin sequence have also accepted amino acid substitutions, with 20 of the 32 sites accepting at least one amino acid substitution in a mammalian species for GLP-2 and 44 of the 69 sites in glicentin being variable, while glucagon and GLP-1 7-37 sequences have substitutions at 11 of 29 and 13 of 31 sites, respectively, and miniglucagon (6 of 11) and OXM (17 of 37) display intermediate levels of variability ( Table 2 , Figure 2 , and Supplementary Figure 5 )
I think there must be less nerve damage with a smaller needle to, that would seem to make sense anyway
Rabenau M, Dillberger B, Gnther M, Krippner S, Butterweck V, Boonen G, et al
And not everyone needs to
The same person might use one protocol for anti-aging and another for injury recovery